Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
Shaw, A.T., Riely, G.J., Bang, Y.-J., Kim, D.-W., Camidge, D.R., Solomon, B.J., Varella-Garcia, M., Iafrate, A.J., Shapiro, G.I., Usari, T., Wang, S.C., Wilner, K.D., Clark, J.W., Ou, S.-H.I.
Published in Annals of oncology (01.07.2019)
Published in Annals of oncology (01.07.2019)
Get full text
Journal Article
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.
Published in Annals of oncology (01.11.2020)
Published in Annals of oncology (01.11.2020)
Get full text
Journal Article
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
Groen, H.J.M., Socinski, M.A., Grossi, F., Juhasz, E., Gridelli, C., Baas, P., Butts, C.A., Chmielowska, E., Usari, T., Selaru, P., Harmon, C., Williams, J.A., Gao, F., Tye, L., Chao, R.C., Blumenschein, G.R.
Published in Annals of oncology (01.09.2013)
Published in Annals of oncology (01.09.2013)
Get full text
Journal Article
Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
Shaw, A., Riely, G.J., Bang, Y.-J., Kim, D.-W., Camidge, D.R., Shapiro, G.I., Usari, T., Wang, S.C., Wilner, K., Clark, J.W., Ou, S.-H.I.
Published in Annals of oncology (01.04.2019)
Published in Annals of oncology (01.04.2019)
Get full text
Journal Article
177P Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
Kim, E., Usari, T., Polli, A., Lewis, I., Wilner, K.
Published in Journal of thoracic oncology (01.04.2016)
Published in Journal of thoracic oncology (01.04.2016)
Get full text
Journal Article
515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)
Tabernero, J., Yoshino, T., Kim, T.W., Yaeger, R., Desai, J., Wasan, H.S., Van Cutsem, E., Ciardiello, F., Maughan, T., Eng, C., Tie, J., Fernandez, M.E. Elez, Lonardi, S., Usari, T., Hahn, E., Dychter, S., Ferrier, G., Zhang, X., Kopetz, S.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
MA06.13 Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study
Smit, E., Ahn, M.-J., Dagogo-Jack, I., Felip, E., Gelsomino, F., Johnson, B., Johnson, M., Negrao, M.V., Offin, M., Ramalingam, S., Sanborn, R., Tsao, A., Wilner, K., Alcasid, A., Usari, T., Zhang, X., Riely, G.
Published in Journal of thoracic oncology (01.10.2024)
Published in Journal of thoracic oncology (01.10.2024)
Get full text
Journal Article
272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)
Martin, M., Rugo, H.S., Hurvitz, S.A., Ettl, J., Roche, H., Lee, K-H., Goodwin, A., Usari, T., Lanzalone, S., Guenzel, C.A., Blum, J., Litton, J.K.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
273P Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial
Hurvitz, S.A., Rugo, H.S., Ettl, J., Martin, M., Roche, H., Lee, K-H., Goodwin, A., Usari, T., Lanzalone, S., Guenzel, C.A., Blum, J., Litton, J.K.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
Riely, G.J., Ahn, M-J., Clarke, J., Dagogo-Jack, I., Felip, E., Gelsomino, F., Goldman, J.W., Hussein, M., Johnson, M.L., Morgensztern, D., Nadal, E., Offin, M.D., Provencio Pulla, M., Ramalingam, S.S., Smit, E.F., Tsao, A.S., Alcasid, A., Usari, T., Wilner, K., Johnson, B.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
P09.53 Comparative Effectiveness of Crizotinib versus Entrectinib in ROS1+ Non-Small Cell Lung Cancer (NSCLC) using Clinical Trial and Real-World Data
Groff, M., Tremblay, G., Iadeluca, L., Wilner, K., Wiltshire, R., Bartolome, L., Usari, T., Cappelleri, J., Camidge, R.
Published in Journal of thoracic oncology (01.03.2021)
Published in Journal of thoracic oncology (01.03.2021)
Get full text
Journal Article
LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)
Tabernero, J., Yoshino, T., Kim, T.W., Yaeger, R., Desai, J., Wasan, H.S., Van Cutsem, E., Ciardiello, F., Maughan, T., Eng, C., Tie, J., Fernandez, M.E. Elez, Lonardi, S., Zhang, X., Chavira, R., Usari, T., Hahn, E., Kopetz, S.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA
Lee, K.-H., Kim, S.-B., Sohn, J., Goodwin, A., Usari, T., Lanzalone, S., Im, Y.-H.
Published in Annals of oncology (01.11.2019)
Published in Annals of oncology (01.11.2019)
Get full text
Journal Article
P45.06 Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
Wu, Y., Lu, S., Yang, J.C., Zhou, J., Seto, T., Ahn, M., Su, W., Yamamoto, N., Kim, D., Paolini, J., Usari, T., Wilner, K., Goto, K.
Published in Journal of thoracic oncology (01.10.2021)
Published in Journal of thoracic oncology (01.10.2021)
Get full text
Journal Article
107OCrizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
Shaw, A, Riely, G J, Bang, Y-J, Kim, D-W, Camidge, D R, Shapiro, G I, Usari, T, Wang, S C, Wilner, K, Clark, J W, Ou, S-H I
Published in Annals of oncology (01.04.2019)
Published in Annals of oncology (01.04.2019)
Get full text
Journal Article
Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014
Mok, T.S.K., Kim, D-W., Wu, Y-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Wilner, K., Blackhall, F., Solomon, B.J.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
Drilon, A., Clark, J., Weiss, J., Ou, S., Camidge, D.R., Solomon, B., Otterson, G., Villaruz, L., Riely, G., Heist, R., Shapiro, G., Murphy, D., Wang, S., Usari, T., Li, S., Wilner, K., Paik, P.
Published in Journal of thoracic oncology (01.10.2018)
Published in Journal of thoracic oncology (01.10.2018)
Get full text
Journal Article
Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001
Shaw, A., Riley, G.J., Bang, Y.-J., Kim, D.-W., Camidge, D.R., Varella-Garcia, M., Lafrate, A.J., Shapiro, G., Winter, M., Usari, T., Wang, S.C., Wilner, K., Clark, J.W., Ou, S.-H.I.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
OA 12.06 Plasma Genomic Profiling and Outcomes of Patients with MET Exon 14-Altered NSCLCs Treated with Crizotinib on PROFILE 1001
Drilon, A., Clark, J., Weiss, J., Ou, S., Camidge, D.R., Solomon, B., Otterson, G., Villaruz, L., Riely, G., Heist, R., Shapiro, G., Murphy, D., Liu, Y., Wang, S., Usari, T., Wilner, K., Paik, P.
Published in Journal of thoracic oncology (01.11.2017)
Published in Journal of thoracic oncology (01.11.2017)
Get full text
Journal Article